Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01438307 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT01438307 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 28 participants.
The verdict
NCT01438307, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
Lung cancer is the leading cause of cancer death worldwide and in the United States. The majority of lung cancers are non-small cell lung cancer (NSCLC). The majority of NSCLC cases are advanced at the time of diagnosis. Chemotherapy has improved overall survival but remains limited at \< 12 months median overall survival. New approaches are needed for second line chemotherapy treatment. Cabazitaxel-XRP6258 has shown increased overall survival in metastatic prostate cancer and it is hopeful it can do the same in advanced NSCLC.
Interventions
- DRUG Cabazitaxel-XRP6258 (3-week cycle)
- DRUG Cabazitaxel-XRP6258 (5-week cycle)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2011-09 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01438307
The ClinicalTrials.gov registry entry for NCT01438307 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cabazitaxel-XRP6258 (3-week cycle) is the first listed.
NCT01438307 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01438307 about?
NCT01438307 is a clinical study titled "Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer". Lung cancer is the leading cause of cancer death worldwide and in the United States. The majority of lung cancers are non-small cell lung cancer (NSCLC). The majority of NSCLC cases are advanced at the time of diagnosis. Chemotherapy has improved overall survival but remains limited at \< 12 months ...
What is the current status of trial NCT01438307?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2011-09. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01438307?
The interventions under investigation include: Cabazitaxel-XRP6258 (3-week cycle) (DRUG), Cabazitaxel-XRP6258 (5-week cycle) (DRUG).
Who is sponsoring clinical trial NCT01438307?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.